FDA Class II Recall: Park Avenue Compounding's Phenylephrine HCI Due to CGMP Deviations
Park Avenue Compounding initiated a Class II recall for 858 syringes of Phenylephrine HCI from its Saint Louis, MO facility, citing CGMP deviations. This event underscores critical supply chain vulnerabilities and the imperative for robust quality assurance in pharmaceutical procurement. Decision-makers must reassess supplier qualification and compliance monitoring to mitigate similar regulatory risks.
FDA Action on Park Avenue Compounding: CGMP Deviations Lead to Phenylephrine HCI Recall
Park Avenue Compounding, operating from its facility at 3662 Park Ave Ste 140, Saint Louis, MO 63110-2512, United States, has initiated a Class II recall (D-0200-2026) for its Phenylephrine HCI, 1000 mcg / 10 mL injectable product. This voluntary, firm-initiated action commenced on September 17, 2025, following identified deviations from Current Good Manufacturing Practices (CGMP). The recall specifically targets 858 syringes from Lot # 20250813-13D65E, which carries an expiration date of February 9, 2026. The affected product, identified by NDC 83863-0104-1, was distributed exclusively within Missouri. For procurement and regulatory affairs directors, this event signals a direct threat to supply chain integrity. CGMP non-compliance, even from a compounding pharmacy, can compromise product quality and patient safety, leading to market withdrawals. While the distribution of this particular recall is localized, it serves as a critical reminder that all suppliers, regardless of size or geographic reach, must adhere to stringent quality standards. Failure to do so exposes your business to supply disruptions, potential legal liabilities, and significant reputational damage.
Implications for Pharmaceutical Procurement and Supply Chain Resilience
The recall of Phenylephrine HCI by Park Avenue Compounding underscores the critical importance of robust quality systems, particularly for sterile injectable products. CGMP deviations can lead to compromised sterility, potency, or purity, posing direct risks to patient health. The Class II classification indicates that exposure to the recalled product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This classification, however, does not diminish the regulatory seriousness of the underlying CGMP failures. For procurement directors, this incident necessitates an immediate re-evaluation of supplier qualification processes, especially for compounded sterile preparations. Supply chain VPs must assess their exposure to regional compounding pharmacies and ensure that comprehensive quality agreements are in place, explicitly detailing CGMP adherence, audit rights, and recall protocols. Business development executives should recognize that the FDA's heightened scrutiny on manufacturing quality impacts market entry strategies and partnership viability, requiring thorough due diligence on potential collaborators' compliance records.
Navigating Regulatory Scrutiny: Broader Industry Context and Risk Mitigation
This recall by Park Avenue Compounding occurs within a broader landscape of intensified FDA oversight concerning manufacturing quality across the pharmaceutical industry. The ChemLifeIntel Knowledge Graph indicates parallel regulatory actions, such as Essential Wellness Pharma's Class II recall of Progesterone Injection due to sterility assurance failures, reported on June 15, 2026. This pattern signals a consistent regulatory focus on manufacturing quality, extending from large-scale manufacturers to specialized compounding facilities. Regulatory affairs heads must proactively monitor FDA enforcement trends, understanding that CGMP compliance is a continuous and evolving requirement. Companies sourcing active pharmaceutical ingredients (APIs) or finished drug products from third parties must implement rigorous vendor management programs, including regular audits and performance reviews, to mitigate risks associated with supplier non-compliance. This proactive stance is crucial for maintaining market access, avoiding costly recalls, and preventing potential import alerts or other enforcement actions that can severely impact revenue streams and operational continuity.